Cathie Wood’s ARK Invest Buys Over 675,000 More Shares of CRISPR

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday. Specifically, these exchange-traded funds bought roughly $65 million worth of CRISPR Therapeutics AG (NASDAQ: CRSP), as the prices of these funds were fairly positive on Wednesday. Note that their performance is mixed in the past year.

ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 150,210 shares of CRISPR, and ARK Innovation ETF (NYSEARCA: ARKK) bought 527,747 shares. At Wednesday’s closing prices, this would have valued the sales at roughly $65.6 million altogether. Even though this is a small fraction of their total holdings, every little bit counts. The innovation ETF is up about 10% and the other is down 1% in the past year.

Note that these same funds also purchased nearly $40 million in CRISPR shares earlier this week.

Check out all the ARK Invest trades for Wednesday as well:

FundDirectionTickerNameShares
ARKGBuyCRSPCRISPR THERAPEUTICS150,210
ARKGBuyDYNSDYNAMICS SPECIAL PURPOSE577
ARKGBuyNTLAINTELLIA THERAPEUTICS51,559
ARKGBuyQSIQUANTUM-SI19,900
ARKGBuySLGCSOMALOGIC399,610
ARKGBuyVCYTVERACYTE11,037
ARKGSellVEEVVEEVA SYSTEMS81,531
ARKKBuyCRSPCRISPR THERAPEUTICS527,747
ARKKBuyBEAMBEAM THERAPEUTICS18,429
ARKKSellPRLBPROTO LABS119,571
ARKKSellSPOTSPOTIFY TECHNOLOGY128,790
ARKKSellUUNITY SOFTWARE142,810
ARKQBuyMKFGMARKFORGED127,526
ARKQBuyTWOU2U1,330
ARKQBuyVLDVELO3D102,790
ARKWBuyGENIGENIUS SPORTS21,618
ARKXBuyMKFGMARKFORGED199,719

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of 247wallst.com.

ALSO READ: Goldman Sachs Says Buy 3 Dividend-Paying Tower Stocks Into Weakness


Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Source: Read Full Article